Robert Richard Flavell MD PhD
Fellow, Nuclear Medicine, University of California, San Francisco
Join to View Full Profile
1275 York AveNew York, NY 10065
Dr. Flavell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Nuclear Medicine, 2016- University of California (San Francisco)Residency, Radiology-Diagnostic, 2011 - 2015
Memorial Sloan Kettering Cancer CenterInternship, Transitional Year, 2010 - 2011
Weill Cornell MedicineClass of 2010
Rockefeller UniversityPhD, Chemical Biology, 2004 - 2009
Certifications & Licensure
CA State Medical License 2011 - 2025
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
Clinical Trials
- [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy Start of enrollment: 2017 May 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Pre- or post-chemotherapy: effect on PSMA uptake.Surekha Yadav, Abuzar Moradi Tuchayi, Moein Moradpour, Fei Jiang, Roxanna Juarez
EJNMMI Research. 2025-04-07 - Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostat...Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath
Journal of Clinical Oncology. 2025-03-26 - Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Anil P Bidkar, Robin Peter, Anju Wadhwa, Kondapa Naidu Bobba, Scott Bidlingmaier
Clinical Cancer Research. 2025-02-13
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Press Mentions
Shuttle Enters Agreement with UCSF to Develop PSMA LigandDecember 19th, 2024
First-of-Its-Kind Study Demonstrates Clinical Impact of Amyloid PET ImagingApril 3rd, 2019- Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareJanuary 26th, 2024
Grant Support
- Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2025–2030
- Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Development of CD46 theranostics for imaging and treatment of multiple myelomaUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- Molecular imaging of novel PARP inhibitor nanomedicine deliveryUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2026
- ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2025
- Mitzi and William Blahd, MD Pilot Research GrantEducation and Research Foundation for Nuclear Medicine and Molecular Imaging2015–2016
- Research fellow grantRadiological Society of North America2015–2016
- T32NIH2014–2015
Committees
- Intern, Society of Nuclear Medicine, Clinical Trials Network 2015 - Present
Research History
- T32 Research Resident2014 - 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
